AFP and hepatocellular carcinoma: The REACH-2 trial will evaluate the efficacy and safety of ramucirumab in a global cohort of participants with hepatocellular carcinoma and elevated baseline AFP (ClinicalTrials.gov Identifier: NCT02435433).